Home
Your Profile
Become a Member/Get Newsletter
Contact Us
Recent Updates
Current Papers
Search All Papers
Search Comments
Research News
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Tech Corner
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Member Directory
Researcher Profiles
Institutes and Labs
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by
NARSAD
, the Brain and Behavior Research Fund, and was created with funding from the
U.S. National Institute of Mental Health
.
Printable version
SZGene - Gene overview of all published SZ-association studies for DTNBP1
Gene:
DTNBP1
(SDY; DBND; HPS7; My031; FLJ30031; MGC20210)
Protein:
dystrobrevin binding protein 1
(dysbindin)
Chromosome:
6
(View:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
X
Y
MT
)
Status:
Updated 21 October 2010
1. Case-Control Studies (by ethnic group)
SZ Cases
Normal Controls
Study
Population
Source
# Polys
# Subjects
(% women)
DX
Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result
Comment
Caucasian
Bakker, 2006
Netherlands
CL
4
(detail)
308
(-)
IV
-
-
580
(-)
-
Negative
Betcheva, 2009
Bulgaria (I)
CL
13
(detail)
185
(-)
IV
-
-
184
(-)
-
Trend
Betcheva, 2009
Bulgaria (II)
CL
1
(detail)
70
(-)
IV
-
-
372
(-)
-
Negative
Datta, 2007
UK
CL
8
(detail)
450
(-)
RDC
-
-
450
(-)
-
Negative
Dutt, 2009
UK, Ireland
CL
2
(detail)
83
(-)
IV
-
-
57
(-)
-
Negative
Dwyer, 2009
UK
CL
7
(detail)
669
(32%)
IV
-
-
710
(33%)
-
Negative
Fallgatter, 2010
Germany
CL
7
(detail)
44
(50%)
IV
-
36.3 + 9.6
(-)
48
(54%)
26.5 + 7.2
(19-63)
n.a.
Funke, 2004
USA (I)
CL
6
(detail)
196
(-)
IV
-
-
467
(52%)
39.3
(-)
Positive
Holliday, 2006
Australia
CL
15
(detail)
194
(-)
M
-
-
180
(-)
-
Negative
Jonsson, 2009
Denmark, Norway, Sweden
CL
11
(detail)
837
(42%)
M
26.5
(-)
45.7
(-)
1473
(42%)
44.1
(-)
Negative
Li, 2005
UK (Scotland)
CL
11
(detail)
580
(28%)
M
-
-
620
(43%)
-
Negative
Morris, 2003
Ireland
CL
8
(detail)
219
(-)
IIIR
-
-
231
(-)
-
Negative
Morris, 2007
Overlaps with
Morris, 2003
CL
2
(detail)
373
(-)
IV
-
-
812
(-)
-
n.a.
Morris, 2007
Overlaps with
Williams, 2004
CL
1
(detail)
373
(-)
IV
-
-
812
(-)
-
n.a.
Pedrosa, 2006
USA (II)
CL
1
(detail)
172
(-)
M
-
-
165
(-)
-
Negative
Peters, 2008
Australia
CL
37
(detail)
336
(20%)
M
-
-
172
(41%)
-
Negative
Rethelyi, 2009
Hungary
CL
4
(detail)
280
(54%)
IV
28.6
(-)
37.6
(-)
230
(57%)
39.9
(-)
Positive
Riley, 2009
Ireland, UK
CL
9
(detail)
1021
(32%)
IIIR
-
-
626
(45%)
-
Positive
Sanders, 2008
USA, Australia
CL
38
(detail)
1870
(31%)
IV
-
-
2002
(53%)
-
Negative
Strohmaier, 2010
Germany
CL
35
(detail)
634
(45%)
IV
-
38.5 + 11.7
(-)
776
(43%)
45.5 + 13.5
(-)
Negative
Tosato, 2007
Italy
CO
11
(detail)
80
(49%)
10
-
42
(-)
106
(47%)
38
(-)
Positive
Van Den Bogaert, 2003
Overlaps with
Strohmaier, 2010 (Germany)
CL
5
(detail)
418
(52%)
IV
-
-
285
(40%)
-
Negative
Van Den Bogaert, 2003
Poland
CL
5
(detail)
294
(41%)
IV
-
-
113
(63%)
-
Negative
Van Den Bogaert, 2003
Sweden
CL
5
(detail)
142
(38%)
IV
-
-
272
(45%)
-
Positive
Vilella, 2007
Spain
PO
11
(detail)
589
(31%)
IV
-
-
615
(48%)
-
Positive
Voisey, 2010
Australia
CL
12
(detail)
160
(14%)
IV
-
36.2 + 12.1
(-)
250
(41%)
36.8 + 12.8
(-)
Positive
Williams, 2004
Overlaps with
Morris, 2003
CL
2
(detail)
219
(101%)
IIIR
25.2 + 12.4
(-)
46 + 8.5
(-)
231
(-)
-
Positive
Williams, 2004
UK, Ireland
CL
20
(detail)
708
(31%)
IV
23.6 + 7.7
(-)
41.8 + 13.5
(-)
711
(33%)
-
Positive
Williams, 2004
Ireland (II)
CL
1
(detail)
219
(-)
IIIR
25.2 + 12.4
(-)
46 + 8.5
(-)
231
(-)
-
Positive
Wood, 2006
USA
CL
15
(detail)
311
(-)
IV
-
-
291
(-)
-
Negative
Zuo, 2009
USA (I)
CL
6
(detail)
235
(-)
IIIR
-
-
298
(-)
-
Positive
African Descent
Funke, 2004
USA (II)
CL
6
(detail)
184
(-)
IV
-
-
74
(59%)
31.9
(-)
Positive
Pedrosa, 2006
USA (I)
CL
1
(detail)
152
(-)
M
-
-
129
(-)
-
Negative
Zuo, 2009
USA (II)
CL
6
(detail)
82
(-)
IIIR
-
-
48
(-)
-
Trend
Asian
Hashimoto, 2009
Japan
CL
1
(detail)
70
(39%)
IV
24.8
(-)
45.1
(-)
165
(67%)
37.3
(-)
n.a.
Hokyo, 2010
Japan
CL
1
(detail)
407
(42%)
IV
-
54.7
(-)
384
(64%)
40.1
(-)
Negative
Joo, 2006
Korea
CL
5
(detail)
194
(35%)
IV
22.7 + 5.7
(-)
35 + 6.2
(-)
351
(50%)
25.9 + 6.4
(-)
Negative
Numakawa, 2004
Japan
CL
6
(detail)
670
(49%)
IV
-
44.2 + 14.6
(-)
588
(51%)
36.2 + 12.4
(-)
Positive
Pae, 2009
Korea
CL
4
(detail)
908
(49%)
M
-
33.7
(-)
601
(49%)
38.9
(-)
Positive
Tochigi, 2006
Japan
CL
12
(detail)
314
(44%)
IV
-
46.3 + 14.9
(-)
314
(44%)
37.6 + 11.3
(-)
Positive
Hispanic
Funke, 2004
USA (III)
CL
6
(detail)
41
(-)
IV
-
-
32
(41%)
32.9
(-)
Negative
Other/Mixed
Pedrosa, 2006
USA (I+II)
CL
3
(detail)
324
(-)
M
-
-
294
(-)
-
Negative
Zinkstok, 2007
Netherlands and Other
CL
7
(detail)
76
(13%)
IV
-
21.5 + 2.9
(-)
31
(26%)
21.5 + 3.1
(-)
Negative
Contact us
if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
2. Family-Based Studies (by ethnic group)
Affecteds
Unaffecteds
Study
Population
# Polys
# Families
# Subjects
(% women)
DX
Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result
Comment
Caucasian
Hall, 2004
South Africa
5
(detail)
233
-
IV
-
-
-
-
Negative
Hall, 2004
USA
5
(detail)
210
-
IV
-
-
-
-
Negative
Holliday, 2006
Australia
15
(detail)
41
114
(-)
M
-
-
135
(-)
-
Negative
Kirov, 2004
Bulgaria
8
(detail)
488
488
(48%)
IV
-
33.1 + 8.2
(-)
976
(50%)
59.9 + 9.2
(-)
Positive
Straub, 2002
Ireland
12
(detail)
270
-
IIIR
-
-
-
-
Positive
Strohmaier, 2010
Overlaps with
Schwab, 2003 (Germany)
35
(detail)
180
-
IV
-
-
-
-
Negative
Turunen, 2007
Finland
17
(detail)
441
865
(39%)
IV
-
-
999
(-)
-
Negative
Van Den Oord, 2003
Ireland
14
(detail)
268
-
IIIR
-
-
-
-
Positive
Wessman, 2009
Re-analysis of Turunen, 2007
15
(detail)
292
-
IV
-
-
-
-
n.a.
Asian
Li, 2005
China
8
(detail)
638
810
(45%)
M
-
-
620
(-)
-
Positive
Liu, 2007
Taiwan
9
(detail)
693
1487
(39%)
IV
22.9 + 6.8
(-)
36 + 9.6
(-)
1300
(52%)
55.7 + 15.4
(-)
Negative
Tang, 2003
China
7
(detail)
233
233
(44%)
IIIR
-
22.8 + 0.5
(-)
466
(50%)
-
Positive
Other/Mixed
De Luca, 2005
Canada
3
(detail)
11
-
IV
-
-
-
-
Trend
Duan, 2007
USA
26
(detail)
136
319
(-)
IIIR
-
-
463
(-)
-
Positive
Fallin, 2005
USA
16
(detail)
263
274
(26%)
IV
19.5 + 4.5
(-)
-
548
(50%)
-
Positive
Holliday, 2006
India
15
(detail)
197
329
(-)
M
-
-
339
(-)
-
Negative
Schwab, 2003
Mixed
6
(detail)
203
281
(-)
IV
-
-
-
-
Positive
Zinkstok, 2007
Overlaps with
Zinkstok, 2007
7
(detail)
76
(13%)
IV
-
21.5 + 2.9
(-)
31
(58%)
22.8 + 3.8
(-)
n.a.
Zinkstok, 2007
Netherlands and Other
7
(detail)
52
52
(-)
IV
-
-
-
-
Negative
Contact us
if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
Source:
Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:
Number of polymorphisms tested per gene and per sample.
Onset Age and Age:
Mean or median age at onset or examination, respectively.
DX:
Criteria used to determine SZ diagnosis -> "IIIR"(DSM-IIIR), "IV" (DSM-IV), "9" (ICD-9), "10" (ICD-10), "M" (Mixed), "RDC" (Research Diagnostic Criteria), "U" (Unknown).
Result:
Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between).
(-)
: Either no data provided or in case of overlap, data included in original study.
SZGene Recent Updates
SZGene Stats
Studies: 1727
Genes: 1008
Polymorphisms: 8788
Meta-analyses: 287
ALSGene
AlzGene
MSGene
PDGene
SZGene
An up-to-date collection of all published genetic association studies.
SRF News
SRF Comments
Text Size
Reset Text Size
Email this page
Research Participants
Collaborators
Copyright © 2005-2024 Schizophrenia Research Forum
Privacy Policy
Disclaimer
Disclosure
Copyright